In a 10-year period, 407 of 350,000 pregnancies showed maternal anti-Kell allo-immunization, i.e., an incidence of 1.16 per 1000 pregnancies. About 88% of Kell immunized women gave a history of previous transfusion. There were 51 pregnancies with Kell positive partners (all Kk) resulting in 10 Kell positive babies, of whom six had a positive direct antiglobulin test (DAGT). There were two stillbirths due to haemolytic disease of the newborn, when the maternal anti-Kell titres were 1/256. One baby was severely anaemic and given a top-up transfusion, and two babies were jaundiced and given phototherapy. A policy for management of Kell sensitized pregnancies is outlined, based upon maternal anti-Kell titre and where appropriate fetal blood sampling.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2257.1990.tb00349.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing.
Lancet Haematol
November 2024
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Department of Clinical Pathology, University Health Network, Toronto, ON, Canada.
Anti-KEL1 antigen (also referred to as anti-Kell, or anti-K) alloimmunisation is the second most common cause of severe haemolytic disease of the fetus and newborn, after anti-rhesus D antigen, and can cause substantial fetal morbidity and mortality. Both fetal erythropoietic suppression and haemolysis contribute to anaemia. Typically, once a clinically significant alloantibody is identified during pregnancy, antibody titration is performed as a screening test to predict the risk of anaemia and the need for maternal-fetal medicine referral.
View Article and Find Full Text PDFSuccessful management of severe Kell alloimmunization in pregnancy with intravenous immune globulin.
Transfus Apher Sci
April 2024
ULB - Erasme Campus, Belgium.
Hemolytic Disease of the Fetus and Newborn (HDFN) is a condition that affects 1 to 2 out of 1000 patients during pregnancy (1). When an alloantibody is present, it is essential to identify its nature in order to organize appropriate follow-up. Kell-mediated HDFN is rare; it occurs in about 5% of Kell alloimmunized pregnant women.
View Article and Find Full Text PDFUpdates in the care of the alloimmunized pregnant patient: A transfusion medicine and clinical laboratory perspective.
Am J Clin Pathol
November 2023
Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, US.
Hemolytic disease in fetuses and newborns due to antibodies against the M-antigen.
Biomedica
December 2021
Inmunohematología, Fundación Santa Fe de Bogotá, Bogotá, D.C., Colombia.
There are few case reports of hemolytic disease in fetuses and newborns (HDFN) caused by alloantibodies against the MNS blood group system. The reason for this dearth is that antibodies toward these antigens are usually IgM, which not only cannot cross the placental circulation but also react at temperatures below 37°C. They are, therefore, of minimal clinical importance.
View Article and Find Full Text PDFThree non-classical mechanisms for anemic disease of the fetus and newborn, based on maternal anti-Kell, anti-Ge3, anti-M, and anti-Jr cases.
Transfus Apher Sci
October 2020
Fukushima Prefectural Hygiene Institute, Fukushima, Japan.
Maternal alloantibody-mediated hemolytic disease of the fetus and newborn (HDFN) ranges from no or mild symptoms to severe hydrops and intrauterine fetal demise. Hemolytic anti-D-mediated HDFN proceeds via a long-known mechanism, to which three other pathways to fetal/neonatal anemia may be added: (0) Fetal erythrocyte destruction can proceed by extravascular phagocytosis. (1) An apoptotic pathway has been described for anti-Kell, and anti-Ge3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!